Roche Molecular Systems, Pleasanton, Calif, has announced the CE marking and launch of its Navify mutation profiler, a clinical software system that provides annotation, interpretation, and clinical reporting of next-generation sequencing (NGS) tests for cancer profling.
The company also announced the launch of its Navify therapy matcher, an optional clinical decision support application that further aids clinicians by linking clinically actionable mutations to relevant therapy options.
The system helps clinicians to interpret NGS oncology tests more easily, and to perform key functions that include classifying detected variants in accordance with up-to-date literature and local medical guidelines, and providing information about actionable therapies and clinical trial options.
Clinical labs looking to develop or install in-house NGS testing face a number of challenges. One obstacle is the complexity of interpretation and the challenge of providing meaningful reporting to clinicians. The Navify mutation profiler empowers diagnostic labs to overcome these challenges by simplifying how labs report their NGS tests.
“We are excited with the launch of Navify mutation profiler and Navify therapy matcher,” says Neil Gunn, head of Roche sequencing solutions. “Together they offer a clinical decision support solution that addresses a major workflow challenge for NGS labs, synthesizing large amounts of medical and scientific data into actionable insights.”
“Precision medicine requires precision in clinical interpretation and reporting,” says Markus Tiemann, MD, a professor at the Hamburg Institute for Hematopathology. “With Navify mutation profiler, our lab has access to the most clinically relevant and up-to-date information, drastically reducing our curation time. The intuitive software produces concise, actionable reports that accelerate our clinicians’ ability to deliver the best treatment options for our patients.”
The Navify decision support portfolio helps healthcare professionals navigate the increasing complexity of medical and scientific information by transforming large amounts of data into actionable insights. With the launch of the profiler, Roche moves one step closer to personalized healthcare. Together with Navify tumor board and the integrated Navify clinical decision support applications, the Navify mutation profiler helps to better bridge precision diagnostics with personalized clinical management.
The Navify portfolio has the power to fundamentally change the way oncology teams manage care for cancer patients across the continuum of care. Additionally, the portfolio is continuously evolving to include additional workflow products and clinical decision support applications that will aid the transformation of healthcare delivery.
For further information, visit Roche.
